Table 1.
Baseline demographic and clinical characteristics of subjects with non-AIDS-defining cancer, AIDS-defining cancer, and the general cohort at enrollment.
| NADC | ADC | Cohort | P valuesa | |
|---|---|---|---|---|
| No. (%) | 115 (45.5) | 138 (54.5) | 2566 | |
| Median age (years) | 45 | 35 | 38 | |
| Age groups (years) [No. (%)] | ||||
| <30 | 6 (5.2) | 22 (15.9) | 392 (15.3) | <0.001 |
| 30–39 | 20 (17.4) | 75 (54.4) | 1116 (43.5) | |
| 40–49 | 62 (53.9) | 32 (23.2) | 785 (30.6) | |
| ≥50 | 27 (23.5) | 9 (6.5) | 273 (10.6) | |
| Gender [No. (%)] | ||||
| Male | 91 (79.1) | 105 (76.1) | 1734 (67.6) | 0.005 |
| Female | 24 (20.9) | 33 (23.9) | 832 (32.4) | |
| Race [No. (%)] | ||||
| White | 29 (25.2) | 41 (29.7) | 583 (22.7) | 0.323 |
| Black | 85 (73.9) | 94 (68.1) | 1935 (75.4) | |
| Other | 1 (0.9) | 3 (2.2) | 48 (1.9) | |
| HIV transmission risk factors [No. (%)]b | ||||
| Men who had sex with men | 40 (36.7) | 73 (55.3) | 731 (29.4) | <0.001 |
| Injection drug use | 53 (48.7) | 34 (25.8) | 1035 (41.6) | <0.001 |
| Heterosexualc | 45 (48.0) | 38 (28.8) | 1192 (47.9) | <0.001 |
| Median CD4 cell count (cells/μl) | 319 | 157 | 281 | |
| CD4 cell count (cells/μl) groups [No. (%)] | ||||
| >350 | 50 (43.5) | 39 (28.3) | 1042 (40.7) | <0.001 |
| 201–350 | 31 (27.0) | 19 (13.8) | 539 (21.0) | |
| 51–200 | 21 (18.3) | 33 (23.9) | 529 (20.7) | |
| ≤50 | 13 (11.3) | 47 (34.1) | 451 (17.6) | |
| Median HIV-1 RNA (log10 copies/ml) | 3.92 | 4.34 | 4.42 | |
| HIV-1 RNA (log10 copies/ml) groups [No. (%)] | ||||
| <2.60 | 16 (14.3) | 19 (14.4) | 330 (14.2) | 0.003 |
| 2.60–3.99 | 30 (26.8) | 14 (10.6) | 520 (22.3) | |
| 4.0–4.99 | 39 (34.8) | 37 (28.0) | 834 (35.8) | |
| ≥5.0 | 27 (24.1) | 62 (47.0) | 648 (27.8) | |
| History of HAART prior to enrolment [No. (%)]d | ||||
| 31 (27.0) | 36 (26.1) | 630 (24.6) | 0.775 | |
| Chronic HBV infection | 15 (13.0) | 15 (10.9) | 227 (8.9) | 0.230 |
| Chronic HCV infection | 57 (49.6) | 41 (29.7) | 1060 (41.3) | 0.004 |
NADC, non-AIDS-defining cancer; ADC, AIDS-defining cancer; HBV, hepatitis B; HCV, hepatitis C.
a
χ2 tests comparing NADC, ADC, and general cohort.
b
Risk factor assignment is not mutually exclusive.
c
History of heterosexual activity with a partner with known HIV infection or with a partner at high risk for HIV infection.
d
Defined in the Methods.